InsidersTradesSigma
Follow the iBio, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, iBio, Inc. has logged 32 insider filings. Market capitalisation: €69.5m. The latest transaction was disclosed on 27 March 2026 (Acquisition). Among the most active insiders: Brenner Martin. Every trade is openly available.
32
Insider Decl.
n/a
Thresholds
€719,288
11 ops.
Buy Volume
€89,965
14 ops.
Sell Volume
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 March 2026
Declarations32 total
12,500 shares@ US$1.642542.2% of flowCommon StockSEC:0001104659-26-036093:0
Canonical exit: 24 Jun 2026 (T+90)
24,835 shares@ US$2.018664.3% of flowCommon StockSEC:0001104659-26-033028:0
Canonical exit: 17 Jun 2026 (T+90)
12,336 shares@ US$2.0220.6% of flowCommon StockSEC:0001104659-26-033021:0
Canonical exit: 17 Jun 2026 (T+90)
9,191 shares@ US$2.72100.0% of flowCommon StockSEC:0001104659-25-003062:0
Canonical exit: 10 Apr 2025 (T+90)
9,191 shares@ US$2.72100.0% of flowCommon StockSEC:0001104659-25-003064:0
Canonical exit: 10 Apr 2025 (T+90)
183,823 shares@ US$2.72100.0% of flowCommon StockSEC:0001104659-25-003059:0
Canonical exit: 10 Apr 2025 (T+90)
9,191 shares@ US$2.7228.9% of flowCommon StockSEC:0001104659-25-003063:0
Canonical exit: 10 Apr 2025 (T+90)
9,191 shares@ US$2.72100.0% of flowCommon StockSEC:0001104659-25-003058:0
Canonical exit: 10 Apr 2025 (T+90)
18,382 shares@ US$2.72100.0% of flowCommon StockSEC:0001104659-25-003061:0
Canonical exit: 10 Apr 2025 (T+90)
1,838 shares@ US$2.72100.0% of flowCommon StockSEC:0001104659-25-003060:0
Canonical exit: 10 Apr 2025 (T+90)
4,881 shares@ US$0.26551.5% of flowCommon StockSEC:0001104659-23-114269:0
5,267 shares@ US$0.30221.8% of flowCommon StockSEC:0001104659-23-107157:0
4,215 shares@ US$0.3111.5% of flowCommon StockSEC:0001104659-23-106379:0
5,011 shares@ US$0.30511.7% of flowCommon StockSEC:0001104659-23-096877:0
4,480 shares@ US$0.51112.5% of flowCommon StockSEC:0001104659-23-085306:0
47,020 shares@ US$0.585329.4% of flowCommon StockSEC:0001104659-23-080733:0
75,833 shares0Common StockSEC:0001104659-23-075015:0
75,833 shares0Common StockSEC:0001104659-23-075015:1
3,859 shares@ US$0.68052.8% of flowCommon StockSEC:0001104659-23-073578:0
4,158 shares@ US$0.9354.3% of flowCommon StockSEC:0001104659-23-063805:0
4,382 shares@ US$1.19985.7% of flowCommon StockSEC:0001104659-23-048952:0
37,500 shares0Common StockSEC:0001104659-23-040818:0
50,000 shares0Common StockSEC:0001104659-23-040819:0
5,213 shares@ US$2.131512.2% of flowCommon StockSEC:0001104659-23-037424:0
3,976 shares@ US$1.777.8% of flowCommon StockSEC:0001104659-23-024785:0
25 of 32 declarations
关于 iBio, Inc.
iBio, Inc. 是一家生物制药公司，专注于开发基于重组蛋白的治疗方法。该公司利用植物蛋白生产平台开发疫苗和生物疗法。